BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the ...

The global RNA targeting small molecule drug discovery market was valued at approximately USD 1.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of more than 20.9% ...

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...

Researchers have developed an RNA-seq method for investigating drug-resistant infections, and we got the inside scoop!

Automation and artificial intelligence (AI) will be key to a new effort to manufacture millions of RNA vaccines in Africa.

The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for ...

Researchers at Purdue University have developed NuFold, a machine learning tool that predicts 3D RNA structures from ...

Ribonucleic acid, commonly known as RNA, is involved in many biological functions, and some, including gene silencing, are ...

With the modality now in early clinical trials, experts say more efficiency, broader editing capabilities and delivery ...

RNA-based therapeutics have rapidly emerged over the past decade, offering a new class of medicines that differ significantly from conventional drugs. These therapies can be programmed to target or ...